Patients reporting severe overactive bladder symptoms: Effects of solifenacin treatment on objective measures and patient-reported outcomes

Capo' J P1, Toglia M2, Forero-Schwanhaeuser S3, He W4

Abstract Category

Detrusor Overactivity

Abstract 582
Read by Title
Scientific Non Discussion Abstract Session 20
1. Internal Medicine Associates of Atlanta, Atlanta, Georgia, USA, 2. Urogynecology Associates of Philadelphia, Media, PA, USA, 3. GlaxoSmithKline, King of Prussia, Pennsylvania, USA, 4. Astellas Pharma US Inc., Deerfield, IL, USA
Links

Abstract

09/07/2025 12:05:04